General Information


DRAVP ID  DRAVPe01726

Peptide Name   N46eg(SARS-CoV (902-947)[K2N,I4S,N9Q,A11E,Q16N,S18V,S23N,A25S,V32D,A37N,A39S,V44Q,Q46E])

Sequence  QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE

Sequence Length  46

UniProt ID  P59594 

Source  Synthetic construct



Activity Information


Target Organism  SARS-CoV

Assay  cell fusion inhibition assay

Activity 

  • [Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=5.07 ± 0.17 μM).

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

  • [Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.

Binding Target  membrane

Mechanism  Binding to the HR2 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.



Structure Information


PDB ID  None

Predicted Structure Download  No predicted structure available

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Stereochemistry  L



Physicochemical Information


Formula  C216H356N66O83

Absent amino acids  CHMPRWY

Common amino acids  Q

Mass  5205.59

Pl  4.51

Basic residues  3

Acidic residues  5

Hydrophobic residues  11

Net charge  -2

Boman Index  -13570

Hydrophobicity  -119.13

Aliphatic Index  74.13

Half Life 

  •     Mammalian:0.8 hour
  •     Yeast:10 min
  •     E.coli:>10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  18



Literature Information


Literature 1

Title   Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.

Pubmed ID   18983873

Reference   Antiviral Res. 2009 Jan;81(1):82-7.

Author   Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.

DOI   10.1016/j.antiviral.2008.10.001